Trial Profile

A Prospective, Phase II, Double Blinded, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Vandetanib Therapy with Gemcitabine Therapy Alone in Locally Advanced or Metastatic Pancreatic Carcinoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Jun 2017 Primary endpoint (Overall survival duration) has not been met as per the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
29 Jan 2014 Accrual to date is 101% according to United Kingdom Clinical Research Network.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com